Credit Suisse Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $340

Credit Suisse maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $310 to $340.

Benzinga · 11/06/2019 12:19

Credit Suisse maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $310 to $340.